Lumos Pharma Inc(LUMO) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.

Current Price

$12.38

RSI

48.191

Beta:

1.47431

March 09, 2021
319K
-7M

-90.762 %
-79.310 %
-98.753 %
34.648 %

$168,000
$936,000
$12,474,000
$28,700,000
$35,768,000
$68,501,000
-457.143 %
-1232.692 %
-130.079 %
-24.627 %
-91.515 %

$-19,636,000
$-42,977,000
$-60,563,000
$-72,510,000
$-90,511,000
$-33,643,000
118.868 %
40.920 %
19.727 %
24.826 %
-62.830 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.